Gracell Biotechnologies Earning Date (GRCL)

USA |NASDAQ |USD

GRCL Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 15, 2022 (est) Sep 30, 2022 - - $-0.06
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 15, 2022 (est) Sep 30, 2022 - - $366.00K

Gracell Biotechnologies's next estimated earnings date (based on same quarter last year's date) is Nov 15, 2022 for the fiscal quarter ending Sep 30, 2022.

GRCL Earnings Date & History Chart

GRCL Earnings & Revenue Forecast

GRCL Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 2 $-0.87 $-1.55 $-0.20
Dec 2023 2 $-1.07 $-1.90 $-0.24

GRCL Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 0 $-1.68 $-1.68 $-1.68
Dec 2023 0 / 0 $-0.39 $-0.39 $-0.39

GRCL Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 3 $30.00K $0.00 $100.00K
Dec 2023 2 $50.00K $0.00 $100.00K

GRCL Earnings Date & Revenue History

GRCL Earnings History

|
Show More
Show More

GRCL Revenue History

|
Show More
Show More

Gracell Biotechnologies Next Earnings Date & Report

GRCL Aug 2022 (FQ) Earnings Date & Report Preview

GRCL's next estimated earnings date (based on same quarter last year's report date) is Nov 15, 2022 for the fiscal quarter ending Sep 30, 2022.

Gracell Biotechnologies Previous Earnings Dates & Reports

GRCL Previous Earnings Date & Report Recap: Jun 2022 (FQ)

Gracell Biotechnologies's previous earnings date was Aug 15, 2022 for its fiscal quarter ended Jun 30, 2022.

GRCL Previous Earnings Date & Report Recap: Dec 2021 (FY)

Gracell Biotechnologies's previous annual earnings date was Mar 14, 2022 for its fiscal year ended Dec 31, 2021.

GRCL's earnings per share (EPS) was $-0.45, beating the consensus analysts forecast of $-1.08 by -58.33% , and lower than the previous year's EPS (Dec 2020) by 181.25%.

Revenues were $366.00K.

The company reported a net income of $-451.75M.

Gracell Biotechnologies reported a free cash flow of $-361.29M for its fiscal year, compared to $-277.55M a year ago.

The company ended the fiscal year with $155.18M in total debt, an increase of 50.83% compared to the previous year.